Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma
AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, Anaplastic Large Cell Lymphoma
About this trial
This is an interventional treatment trial for AIDS-related Peripheral/Systemic Lymphoma
Eligibility Criteria
Inclusion Criteria: Histologically confirmed solid tumor or lymphoma Refractory to standard therapy or no standard therapy exists Measurable or evaluable disease No active brain metastases Previously treated brain metastases allowed provided the patient is not currently receiving corticosteroids Primary brain neoplasms allowed, regardless of corticosteroid use Performance status - Karnofsky 70-100% WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 No life-threatening bleeding diathesis within the past 6 months Bilirubin normal (unless due to Gilbert's syndrome) No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No prior proven gastric or duodenal ulcer No clinically significant gastrointestinal blood loss within the past 6 weeks Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No prior CNS hemorrhage No psychiatric illness or social situation that would preclude study compliance No other concurrent uncontrolled illness No ongoing or active infection No prior cilengitide (EMD 121974) No other concurrent biologic therapy More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered No concurrent chemotherapy See Disease Characteristics More than 4 weeks since prior radiotherapy and recovered No concurrent palliative radiotherapy No other concurrent anticancer agents or therapies intended to treat the malignancy No other concurrent investigational agents No concurrent anticoagulation therapy that increases INR or aPTT above the normal range Line prophylaxis allowed
Sites / Locations
- University of Chicago Comprehensive Cancer Center
Arms of the Study
Arm 1
Experimental
Treatment (cilengitide)
Patients receive cilengitide (EMD 121974) IV continuously on weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of EMD 121974 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.